NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 231 filers reported holding NEVRO CORP in Q4 2020. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $1,864,000 | +182.9% | 11,245 | +137.9% | 0.01% | +150.0% |
| Q1 2021 | $659,000 | -48.8% | 4,726 | -36.5% | 0.00% | -50.0% |
| Q4 2020 | $1,288,000 | +273.3% | 7,442 | +200.1% | 0.00% | +300.0% |
| Q3 2020 | $345,000 | +31.7% | 2,480 | -24.5% | 0.00% | 0.0% |
| Q2 2018 | $262,000 | +1.9% | 3,285 | +10.7% | 0.00% | -50.0% |
| Q1 2018 | $257,000 | +26.0% | 2,967 | 0.0% | 0.00% | +100.0% |
| Q4 2017 | $204,000 | -25.3% | 2,967 | -1.1% | 0.00% | -50.0% |
| Q3 2017 | $273,000 | +17.2% | 3,001 | -4.2% | 0.00% | 0.0% |
| Q2 2017 | $233,000 | -20.2% | 3,133 | -22.0% | 0.00% | -33.3% |
| Q4 2016 | $292,000 | -13.6% | 4,016 | +24.0% | 0.00% | 0.0% |
| Q3 2016 | $338,000 | +28.0% | 3,240 | -9.6% | 0.00% | 0.0% |
| Q2 2016 | $264,000 | +28.2% | 3,583 | -2.2% | 0.00% | +50.0% |
| Q1 2016 | $206,000 | – | 3,664 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
| Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
| Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
| Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
| PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
| Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
| Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
| Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
| HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
| FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |